Qiagen N.V.

QIAGEN N.V. / Sonstiges

Ad-hoc-Meldung nach § 15 WpHG übermittelt durch die DGAP - ein Unternehmen der EquityStory AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

---

QIAGEN gibt Preisfestsetzung der US$ 270.000.000, 3,25% Wandelschuldverschreibung (Endfälligkeit 2026) bekannt
Venlo, Niederlande, 9. Mai 2006 – Die QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) meldet heute die Preisfestsetzung der nicht nachrangigen Wandelschuldverschreibungen (senior unsubordinated convertible notes) über US$ 270 Millionen mit einer Endfälligkeit im Jahr 2026, die in einer Mindeststückelung von $100.000 an institutionelle Anleger außerhalb der USA auf der Grundlage der Regulation S des US Securities Act von 1933, in der jeweils maßgeblichen Fassung, verkauft wurden. Die Gesellschaft beabsichtigt darüber hinaus, den Ersterwerbern der Wandelschuldverschreibung eine Option auf den Erwerb weiterer Wandelschuldverschreibungen bis zu einem Gesamtnennwert in Höhe von USD 30 Millionen anzubieten. Angesichts der positiven Aufnahme und der starken Nachfrage dieses Angebotes im Finanzmarkt, hat das Unternehmen das Volumen der Wandelschuldverschreibungen von den vorher angekündigten US$220 Millionen (plus der Option für Ersterwerber weitere Wandelschuldverschreibungen bis zu einem Gesamtnennwert in Höhe von USD 30 Millionen zu erwerben) erhöht.

Die Wandelschuldverschreibungen können, vorbehaltlich späterer Anpassungen, zum anfänglichen Wandlungspreis von ungefähr US$ 20,00 pro Aktie gewandelt werden. Die Wandelschuldverschreibung wird mit einem Zinskupon von 3,25% ausgestattet. Die Zinsen sind halbjährig, jeweils nachträglich zahlbar.
Die Gesellschaft beabsichtigt, die Erlöse aus der Begebung der Wandelschuldverschreibungen zur Optimierung ihrer Bilanzstruktur (mögliche Rückzahlung von Verbindlichkeiten) und zur Finanzierung allgemeiner gesellschaftlicher Zwecke und Akquisitionsvorhaben zu verwenden.
Die Wandelschuldverschreibung wird durch eine 100%ige Tochtergesellschaft der QIAGEN ausgegeben und durch eine Garantie seitens QIAGEN abgesichert. Der Ausgabetag der Wandelschuldverschreibung wird voraussichtlich der 16. Mai 2006 sein. Eine Börsennotierung der Wandelschuldverschreibungen an der Luxemburger Börse wird beantragt.

In connection with the issue of the Notes, the initial purchasers, or any of them acting as stabilization agent, may over-allot or effect transactions with a view to supporting the market price of the Notes or the common shares deliverable upon conversion of the Notes at levels above those which might otherwise prevail. Such transactions may be effected in the over-the-counter markets or otherwise. However, there is no assurance that the initial purchasers or a stabilization agent will undertake stabilization action. Any such stabilization action may begin on the date of adequate public disclosure of the final terms of the offer in relation to such Notes and, if commenced, may be discontinued at any time and must end no later than (i) 30 calendar days after the date on which the issuer receives the proceeds of the issue or (ii) 60 calendar days after the date of allotment of the Notes, whichever is the earlier.
If the initial purchasers sell more than $270,000,000 aggregate principal amount of the Notes, the initial purchasers have an option to subscribe for up to an additional $30,000,000 aggregate principal amount of the Notes from the issuer to cover such sales. The initial purchasers may exercise this option for 30 days from May 9, 2006.

This announcement is for general information only and does not form part of any offer to sell, or the solicitation of any offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions.

This announcement is directed only at the following persons in the United Kingdom: investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); and high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. If you are in the United Kingdom and do not fall into one of the above categories, any investment or investment activity to which this announcement relates is not available to you, and will not be engaged in with you, and you should not act upon, or rely on, this announcement.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, including statements regarding QIAGEN’s intention to commence and complete the offering and the intended uses of the proceeds of any such offering. To the extent that any of the statements contained herein are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations due to the level and timing of customers’ funding, budgets, and other factors), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors’ products, market acceptance of QIAGEN’s new products, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission (SEC).

The Notes being offered and the common shares issuable upon conversion of the Notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful.



IR QIAGEN N.V.; phone +49 2103 29 11710; fax +49 2103 29 21710; email ir@qiagen.com


DGAP 09.05.2006 

---

 
Sprache:      Deutsch
Emittent:     QIAGEN N.V.
              Spoorstraat 50
              NL-5911 KJ Venlo Niederlande
Telefon:      +31 77320 840-0
Fax:          +31 77320 840-9
Email:        qiagen@qiagen.com
WWW:          www.qiagen.com
ISIN:         NL0000240000
WKN:          901626
Indizes:      TecDAX
Börsen: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Stuttgart, München, Hamburg, Düsseldorf  
Ende der Mitteilung DGAP News-Service  

---